WO2021071321A1 - 원화, 위령선, 및 천마의 복합 생약 추출물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물 - Google Patents
원화, 위령선, 및 천마의 복합 생약 추출물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2021071321A1 WO2021071321A1 PCT/KR2020/013812 KR2020013812W WO2021071321A1 WO 2021071321 A1 WO2021071321 A1 WO 2021071321A1 KR 2020013812 W KR2020013812 W KR 2020013812W WO 2021071321 A1 WO2021071321 A1 WO 2021071321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- wiryeongseon
- neurodegenerative diseases
- wonhwa
- preventing
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a pharmaceutical composition for the prevention or treatment of neurodegenerative diseases comprising a complex herbal extract of Wonhwa, Wiryeongseon, and Chunma as an active ingredient.
- the present invention relates to a food composition or feed composition for preventing or improving neurodegenerative diseases comprising the herbal extract as an active ingredient.
- Neurodegenerative brain disease is a disease that causes various conditions such as motor disorders, memory disorders, and cognitive disorders due to neurodegenerative changes.
- Parkinson's disease is a dopaminergic neuronal cell containing the melanin pigment of substantia nigra pars compactra (SNpc) through various stimuli such as excessive reactive oxygen species production, oxidative stress, misfolded proteins and impaired mitochondrial function. It is known as a disease caused by death and dopamine deficiency in striatum.
- Dopamine is produced in the black matter of the brain, and the neurons of the black matter are intricately connected to the motor cortex and other parts of the brain, and are connected to a site called the basal ganglia that allows the body to perform smoothly and accurately. Regulates the function of the basal ganglia.
- Parkinson's disease which is caused by a lack of dopamine secreted from the black matter, is accompanied by symptoms such as tremor, bradykinesia, rigidity, postural instability, and akinesia.
- Parkinson's disease treatment methods to date have mainly used dopamine supplementation by administering L-dopa, a dopamine precursor, but it is known that continuous use of L-dopa causes serious side effects in many clinical studies (McGeer PL). , McGeer EG. Glial reactions in Parkinson's disease.Mov Disord. 2008;23(4):474-83.). Therefore, the development of natural drugs with fewer side effects than synthetic drugs in Parkinson's disease can be of great help to patients.
- compositions for preventing or treating Parkinson's disease containing Baekryum extract as an active ingredient, and Mokdanskin extract.
- a composition for preventing or treating Parkinson's disease is known.
- the won (Genkwae Flos) is thymelaeaceae (Thymeleaceae) Daphne Genkwa as buds of (Daphne genkwa Siebold et Zuccarini), menopause ( ⁇ ), parenteral ( ⁇ ), it acts on nerve ( ⁇ ), and diuretic And it has the effect of removing phlegm, and has been used as an herbal medicine to treat asthma, seawater, tree species, and food poisoning.
- Clematidis Radix is Clematis manshurica Ruprecht of Ranunculaceae and Clematis hexapetala Pallas, Clematis chinensis Osbeck, Clematis chinensis Osbeck, Clematis trichotoma Ruprecht, and Clematis trichotoma Ruprecht, which are close to the genus that can be replaced. the roots and the roots of clematis ahreuman di (clematis armandii) stems.
- Wiryeongseon removes customs and treats joint flexion, limb paralysis, low back pain, limb pain, muscle paralysis, and bruises, and is used for pain caused by hyperfunction of the five intestines and obstruction of the meridians. The pharmacological action lowers blood pressure and excites smooth muscles. , Diuretic, hypoglycemic, analgesic, and antibacterial effects have been reported. Gastrodiae Rhizoma is a steamed and dried tuber of Gastrodia elata BLUME of the Orchidaceae family.It acts on the liver and is used for convulsive seizures, tetanus, acute panic attacks, dizziness, headaches, nervous breakdowns, and headaches. In addition, Chunma shows sedation, anticonvulsant, analgesic, anti-inflammatory, increased heart and brain blood flow, lowered blood pressure, increased antioxidant power, and immune activation.
- the present inventors continued research to develop a method for treating neurodegenerative diseases, and when using complex herbal extracts of Wonhwa, Wiryeongseon, and Chunma, rather than using each single extract.
- the present invention was completed by discovering that there is a remarkably excellent therapeutic effect.
- Patent Document 1 Korean Patent Registration No. 10-1436017
- Patent Document 2 Korean Patent Registration No. 10-1166481
- the present invention is to provide a pharmaceutical composition for the prevention or treatment of neurodegenerative diseases comprising a complex herbal extract of Wonhwa, Wiryeongseon, and/or Chunma as an active ingredient.
- An object of the present invention is to provide a food composition for preventing or improving neurodegenerative diseases, comprising a compound herbal extract of Wonhwa, Wiryeongseon, and/or Chunma as an active ingredient.
- An object of the present invention is to provide a feed composition for preventing or improving neurodegenerative diseases comprising a compound herbal extract of Wonhwa, Wiryeongseon, and/or Chunma as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising extracts of two or more herbal medicines selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma.
- the pharmaceutical composition may include a herbal extract of Wonhwa and Wiryeongseon.
- the pharmaceutical composition may include herbal extracts of Wonhwa and Cheonma.
- the pharmaceutical composition may include herbal extracts of Wiryeongseon and Cheonma.
- the pharmaceutical composition may include herbal extracts of Wonhwa, Wiryeongseon, and Chunma.
- the herbal extract may be extracted with a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, a mixed solvent thereof, and a non-polar solvent.
- a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, a mixed solvent thereof, and a non-polar solvent.
- it is 0.01% to 90% ethanol extract, and most preferably, it is 50% to 70% ethanol extract.
- the neurodegenerative disease is Parkinson's disease, Alzheimer's disease, Peak's disease, Huntington's disease, Lou Gehrig's disease, prion disease, Lewy body dementia, multiple system atrophy, progressive nuclear paralysis, Friedreich's ataxia, temporal lobe epilepsy, or stroke.
- Parkinson's disease is Parkinson's disease.
- the pharmaceutical composition comprises a herbal extract of Wonhwa and Wiryeongseon, and the combined weight ratio of the two herbal medicines or herbal extracts thereof may be 1: 1 to 20, preferably 1: 5 to 15 , More preferably 1:10.
- the pharmaceutical composition comprises herbal extracts of Wonhwa and Cheonma, and the blending weight ratio of the two herbal medicines or herbal extracts thereof may be 1: 1 to 20, preferably 1: 5 to 15 , More preferably 1:10.
- the pharmaceutical composition comprises herbal extracts of Wiryeongseon and Cheonma, and the weight ratio of the two herbal medicines or herbal extracts thereof may be 1:0.05 to 20, and most preferably 1: 1.
- the pharmaceutical composition comprises a herbal extract of Wonhwa, Wiryeongseon, and Chunma, and the blending weight ratio of Wonhwa, Wiryeongseon, and Cheonma may be 1: 1 to 20: 1 to 20, preferably 1: 5 to 15: 5 to 15, most preferably 1: 10: 10.
- the pharmaceutical composition can prevent or treat neurodegenerative diseases by improving behavioral ability.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting toxic cell death in neurons.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting the production of reactive oxygen species (ROS) in neurons.
- ROS reactive oxygen species
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by protecting mitochondrial function in neurons.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting apoptosis of neurons.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting the production of nitric oxide (NO).
- NO nitric oxide
- the present invention also provides a food composition for preventing or improving neurodegenerative diseases comprising two or more herbal extracts selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma.
- the present invention also provides a feed composition for preventing or improving neurodegenerative diseases comprising two or more herbal extracts selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma.
- the pharmaceutical composition comprising the extract of the herbal medicine Wonhwa, Wiryeongseon, and/or Cheonma of the present invention as an active ingredient exhibits excellent therapeutic effect in neurodegenerative diseases, particularly Parkinson's disease, and can be used as a novel therapeutic agent.
- composition of the present invention can be used as a safe therapeutic agent to reduce side effects of existing therapeutic agents by including a natural product as an active ingredient.
- FIG. 1 is a graph showing the results of the Rotarod test in a Rotenone-induced Parkinson's disease animal model (####: p ⁇ 0.0001; ****: p ⁇ 0.0001 (Rotenone group and t-test); *: p ⁇ 0.05 (Rotenone group and t-test)).
- Figure 2 is a graph showing the cell survival rate when using the herbal extract of the present invention (####: p ⁇ 0.0001; ****: p ⁇ 0.0001 (MPP group and t-test); ***: p ⁇ 0.001 (MPP group and t-test)).
- Figure 3 is a graph showing the production rate of intracellular reactive oxygen species (ROS) when the herbal extract of the present invention is used (##: p ⁇ 0.01; **: p ⁇ 0.01 (MPP group and t-test)).
- ROS reactive oxygen species
- Figure 4 is a graph showing the mitochondrial function protective ability in the case of using the herbal extract of the present invention as a TMRE measurement rate (####: p ⁇ 0.0001; *: p ⁇ 0.05 (MPP group and t-test)).
- FIG. 5 is a graph showing the ability to reduce apoptosis when the herbal extract of the present invention is used (####: p ⁇ 0.0001; ****: p ⁇ 0.0001 (MPP group and t-test); ***: p ⁇ 0.001 (MPP group and t-test)).
- FIG. 6 is a graph showing the result of measuring the amount of nitric oxide (NO) production when the herbal extract of the present invention is used (####: p ⁇ 0.0001; ****: p ⁇ 0.0001 (LPS group and t- test); ***: p ⁇ 0.001 (LPS group and t-test)).
- FIG. 7 is a graph showing the Rotarod test results in a Rotenone-induced Parkinson's disease animal model (####: p ⁇ 0.0001; ***: p ⁇ 0.001 (Rotenone group and t-test); **: p ⁇ 0.01 (Rotenone group and t-test)).
- FIG. 8 is a graph showing the result of measuring the amount of nitric oxide (NO) production when the herbal extract of the present invention is used (####: p ⁇ 0.0001; **: p ⁇ 0.01 (LPS group and t-test) ; *: p ⁇ 0.05 (LPS group and t-test)).
- 9A and 9B are graphs showing the effect of protecting cells against MPP+ or 6-OHDA toxicity when using the herbal extract of the present invention.
- FIG. 10 is a graph showing the results of the Pole test in an MPTP-induced Parkinson's disease animal model.
- FIG. 11 is a graph showing the results of the Rotarod test in an MPTP-induced Parkinson's disease animal model.
- the present invention relates to a pharmaceutical composition for the prevention or treatment of neurodegenerative diseases comprising extracts of two or more herbal medicines selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma.
- the pharmaceutical composition may include a herbal extract of Wonhwa and Wiryeongseon.
- the pharmaceutical composition may include herbal extracts of Wonhwa and Cheonma.
- the pharmaceutical composition may include herbal extracts of Wiryeongseon and Cheonma.
- the pharmaceutical composition may include herbal extracts of Wonhwa, Wiryeongseon, and Chunma.
- herbal medicine extract or “complex herbal medicine extract” as used herein, as an active ingredient of the pharmaceutical composition of the present invention, includes extracts extracted from herbal medicines selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma, or these herbal medicines It may include an extract extracted from a mixture of.
- the pharmaceutical composition comprises a herbal extract of Wonhwa and Wiryeongseon, and the combined weight ratio of the two herbal medicines or herbal extracts thereof may be 1: 1 to 20, preferably 1: 5 to 15 , More preferably 1:10.
- the pharmaceutical composition comprises herbal extracts of Wonhwa and Cheonma, and the blending weight ratio of the two herbal medicines or herbal extracts thereof may be 1: 1 to 20, preferably 1: 5 to 15 , More preferably 1:10.
- the pharmaceutical composition comprises herbal extracts of Wiryeongseon and Cheonma, and the weight ratio of the two herbal medicines or herbal extracts thereof may be 1:0.05 to 20, and most preferably 1: 1.
- the pharmaceutical composition comprises a herbal extract of Wonhwa, Wiryeongseon, and Chunma, and the blending weight ratio of Wonhwa, Wiryeongseon, and Cheonma may be 1: 1 to 20: 1 to 20, preferably 1: 5 to 15: 5 to 15, most preferably 1: 10: 10.
- composition of the present invention may further include extracts of other herbal medicines known in the art to have the same or similar effect as that of the composition of the present invention.
- the pharmaceutical composition of the present invention may further include an active ingredient known to be effective in treating neurodegenerative diseases in the art.
- an active ingredient known to be effective in treating neurodegenerative diseases in the art. Examples include L-dopa or dopamine agonists, MAO-A, B inhibitors, neuroprotective agents, and the like.
- composition of the present invention may further include an active ingredient that exhibits an effect on diseases other than neurodegenerative diseases.
- the herbal extract of the present invention When used together with an additional active ingredient, the herbal extract and the additional active ingredient may be administered simultaneously as one formulation, or may be administered simultaneously or sequentially as separate formulations.
- composition of the present invention may be used alone or in combination with surgery, hormone therapy, drug therapy, or methods using biological response modifiers to treat neurodegenerative diseases.
- the herbal extract used in the present invention can be obtained using a conventional extraction solvent known in the art.
- a polar solvent or a non-polar solvent may be used.
- Polar solvents include water, C1 to C6 alcohols (eg, methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol and normal-butanol, etc.), acetic acid, or a mixture of the polar solvents.
- Non-polar solvents include acetone, acetonitrile, ethyl acetate, methyl acetate, butyl acetate, fluoroalkane, hexane, ether, chloroform, dichloromethane, or mixtures of the above non-polar solvents.
- the herbal extract may be extracted with a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, a mixed solvent thereof, and a non-polar solvent.
- a solvent selected from the group consisting of water, C1 to C6 alcohol, acetic acid, a mixed solvent thereof, and a non-polar solvent.
- it is 0.01% to 90% ethanol extract, most preferably 50% to 70% ethanol extract.
- the herbal extract used in the present invention may be extracted through hot water extraction, cold needle extraction, reflux cooling extraction, ultrasonic extraction, or conventional extraction methods known in the art.
- extract means commonly used as a crude extract in the art, but also includes a fraction obtained by further fractionating the extract in a broad sense. That is, the herbal extract includes not only those obtained using the above-described solvent, but also those obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a certain molecular weight cut-off value, separation by various chromatographs (made for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through the purification method are also included in the herbal extract of the present invention.
- the neurodegenerative disease is Parkinson's disease, Alzheimer's disease, Peak's disease, Huntington's disease, Lou Gehrig's disease, prion disease, Lewy body dementia, multiple system atrophy, progressive nuclear paralysis, Friedreich's ataxia, temporal lobe epilepsy, or stroke.
- Parkinson's disease is Parkinson's disease.
- neurodegenerative includes all of the transition of nerve cells from a normal state to a deficient state, genetic decline, and sporadic decline, and in one or several parts of the nervous system. It involves the death of nerve cells, which are slowly and constantly progressing.
- prevention refers to all actions of inhibiting or delaying the onset of neurodegenerative diseases by administration of the pharmaceutical composition according to the present invention, and “treatment” refers to the treatment of neurodegenerative diseases by administration of the pharmaceutical composition. It refers to any action in which symptoms of suspected and affected individuals are improved or beneficially altered.
- the pharmaceutical composition can prevent or treat neurodegenerative diseases by improving behavioral ability.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting toxic cell death in neurons.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting the production of reactive oxygen species (ROS) in neurons.
- ROS reactive oxygen species
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by protecting mitochondrial function in neurons.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting apoptosis of neurons.
- the pharmaceutical composition may prevent or treat neurodegenerative diseases by inhibiting the production of nitric oxide (NO).
- NO nitric oxide
- the present invention also provides a food composition for preventing or improving neurodegenerative diseases comprising two or more herbal extracts selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma.
- the term “improvement” refers to any action that at least reduces the severity of a parameter, such as a symptom, associated with the condition being treated by administration of a composition comprising an extract of the present invention.
- the food composition of the present invention includes health functional foods and health foods.
- the food composition of the present invention can be taken for a long time.
- the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof. , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like.
- the present invention provides a feed composition for preventing or improving neurodegenerative diseases comprising two or more herbal extracts selected from the group consisting of Wonhwa, Wiryeongseon, and Chunma.
- Washed and dried Wonhwa, Wiryeongseon, and Cheonma were used. Each 75 g of Wonhwa, Wiryeongseon, and Chunma herbal medicines were added with a 10-fold 70% (v/v) aqueous ethanol solution, stirred at room temperature for 72 hours, and extracted to obtain an extract. Thereafter, each of the extracts was filtered, concentrated under reduced pressure at 50-65° C., and then lyophilized to obtain a powdery single herbal extract.
- Washed and dried Wonhwa, Wiryeongseon, and Cheonma herbal medicines are mixed to a total of 75 g in a weight ratio of 1:1:1, and then extracted with 10 times 70% (v/v) ethanol aqueous solution and stirred well at room temperature for 72 hours. I did. Thereafter, the extract was filtered, concentrated under reduced pressure at 50-65° C., and then lyophilized to obtain a powdery complex herbal extract (mixed extract).
- the washed and dried herbal medicines of Wiryeongseon and Cheonma were mixed to a total of 80 g in a weight ratio of 1:1, and then a 10-fold 70% (v/v) aqueous ethanol solution was added, followed by extraction with good stirring at room temperature for 72 hours. Thereafter, the extract was filtered, concentrated under reduced pressure at 50-65° C., and then lyophilized to obtain a powdery complex herbal extract (mixed extract).
- a complex herbal extract was prepared as follows, and used in the experiments of Examples 9 to 11. In the case of the original painting, it was crushed to a size that passes through a sieve of control (4,750 ⁇ m), and in the case of the Wiryeongseon and Chunma, it was used in the experiment.
- the Wonhwa, Wiryeongseon, and Cheonma were mixed according to the weight ratio (w/w) shown in Table 1, and then a 10-fold 70% ethanol (v/v) aqueous solution was added and extracted at room temperature for 72 hours. The extract was filtered, concentrated under reduced pressure at 50-65° C., and then freeze-dried to obtain a powdery complex herbal extract.
- Rotenone is a substance used as an insecticide, and inhibits mitochondrial activity by inhibiting the mitochondrial electron transport system. In this case, brain cells are killed, resulting in decreased motor function. Therefore, in order to verify the effect of improving the behavioral ability of the extract of the complex herbal medicine, an experiment was performed to confirm the motor function in the Rotenone-induced Parkinson's disease animal model.
- mice 5-week-old male C57BL/6 mice (Orient Bio Inc., Republic of Korea) weighing 20-22 g were used. Animals were maintained at a room temperature of 23 ⁇ 1° C. with 12 hours of daytime and 12 hours of night cycle following the guidelines of NIH (NIH publication No. 85-23, revised 1985). The mice were randomly divided into 7 groups as follows to perform an in vivo experiment.
- each of the 4 extracts was orally administered to mice for 21 days.
- intraperitoneal administration i.p.
- 1mg/kg/day Rotenone dissolved in saline was administered intraperitoneally (i.p.) for 14 days from 7 days after the start of the extract administration.
- Rotarod test was performed to confirm motor functionality.
- the Rotarod test is a test that measures the running time on a rotating cylinder, and ROTA-ROD TREADMILL DJ345 (Daejong Machine Industries, Korea) was used. Before proceeding with this experiment, the mice were trained three times to run for 5 minutes on a cylinder rotating at a speed of 5, 15 rpm two days and a day before to become accustomed to the device.
- the behavioral ability was only 11.9% (88.1% decrease) compared to the normal group without Rotenone administration.
- the complex herbal extracts prepared in Preparation Example 2 were administered at a concentration of 1, 3, and 10 mg/kg, the behavioral ability was improved to 19.0%, 44.8%, and 75.0% levels, respectively, compared to the normal group. It was confirmed that the ability reduction phenomenon was suppressed.
- the behavioral ability was slightly increased or similar to that of the negative control group, and the degree of improvement in the behavioral ability was lower than in the group administered with the complex herbal extract.
- the degree of behavioral improvement in the positive control group administered with 25 mg/kg of L-DOPA was similar to that of the group administered with 3 mg/kg of the complex herbal extract, and the group administered with 10 mg/kg of the complex herbal extract was treated with L-DOPA.
- the degree of improvement in behavioral ability was better than that of the administered positive control group.
- the complex herbal extracts significantly improved the behavioral ability than the negative control as well as the single herbal extracts. It was confirmed that it can be used to treat Parkinson's disease because it exhibits similar or superior effects at a lower dose even when compared to the case where L-DOPA, a precursor of dopamine, was administered.
- human neuroblastoma SH-SY5Y cells contain 10% fetal bovine serum (Fetal Bovine Serum, FBS, Gibco TM , USA) and antibiotics (1% Penicillin, Streptomycin [P/S], Gibco-BRL, USA) It was cultured in RPMI 1640 medium (Gibco TM , USA) medium. The incubator was kept at a temperature of 37°C, and a gas mixed with 95% air and 5% CO2 was continuously supplied to obtain appropriate conditions for cell culture. The cells were coated with PDL (Poly-D-lysine, Sigma-Aldrich, USA) in a 96-well plate at 1X concentration condition, washed with PBS and dried, and then the cells were cultured. Cells were cultured 24 hours before the experiment so as to be 5 ⁇ 10 4 cells/well. When an appropriate number of cells were cultured, the cells were differentiated by replacing them with a medium containing 0.5% FBS and culturing for an additional 24 hours.
- FBS Fetal Bovine
- the complex herbal extracts of Wonhwa, Wiryeongseon and Cheonma prepared in Preparation Example 2 were treated in a 96-well plate in which the SH-SY5Y cell line was cultured at a concentration of 1, 10, 100 ⁇ g/ml for 30 minutes, and then 2 mM MPP+ was treated. After 48 hours of MPP+ treatment, 100 ⁇ l of a 10% WST-1 solution was added to a 96-well plate. After reacting in an incubator at 37° C. for 30 minutes, absorbance was measured at 450 and 630 nm wavelength values, and the results are shown in FIG. 2.
- the complex herbal extracts of Wonhwa, Wiryeongseon and Chunma prepared in Preparation Example 2 were treated with SH-SY5Y cells at a concentration of 1, 10, and 100 ⁇ g/ml for 30 minutes, followed by treatment with 2 mM MPP+. After 48 hours of MPP+ treatment, DCF-DA was treated in a 96-well plate at a concentration of 10 ⁇ M for 30 minutes. After washing once with PBS, fluorescence was measured in the wavelength range of 485 and 530 nm.
- the SH-SY5Y cells cultured in Example 2 were treated with the complex herbal extracts of Wonhwa, Wiryeongseon and Chunma prepared in Preparation Example 2 at a concentration of 100 ⁇ g/ml for 30 minutes, and then 2 mM MPP+ for 48 hours. I did. Thereafter, TMRE was treated for 30 minutes at a concentration of 0.5 ⁇ M. After washing once with PBS, 100 ⁇ l of PBS was added to each well. Fluorescence was measured in the wavelength region of 549 and 575 nm, and the results are shown in FIG. 4.
- Caspase is a type of cysteine protease, a protein essential for programmed apoptosis called apoptosis. Caspase-activated apoptosis induces apoptosis and induces apoptosis of related cells. In Parkinson's disease, brain cell apoptosis exacerbates the disease. When caspase reacts with the Caspase-Glo reagent containing DEVD luciferin, it encounters ATP and emits light.
- the SH-SY5Y cells cultured in Example 2 were treated with the complex herbal extracts of Wonhwa, Wiryeongseon and Chunma prepared in Preparation Example 2 at a concentration of 1, 10, 100 ⁇ g/ml for 30 minutes, and 2 mM MPP+ was 48 Treated for hours. Thereafter, Caspase-Glo buffer and substrate (Promega, USA) were mixed, 50 ⁇ l was added to each well, and the mixture was treated at room temperature for 30 minutes in the absence of light.
- BV2 cells in DMEM medium (Gibco TM , USA) containing fetal bovine serum (Fetal Bovine Serum, FBS, Gibco TM , USA) and antibiotics (1% Penicillin, Streptomycin [P/S] Gibco-BRL, USA) Cultured. Specifically, the incubator was kept at a temperature of 37°C, and a gas mixed with 95% air and 5% CO2 was continuously supplied to ensure that appropriate conditions for cell culture were established. Cells were cultured 24 hours before the experiment so that the cells were 3x10 4 cells/well in a 12-well plate.
- the complex herbal extracts of Wonhwa, Wiryeongseon and Cheonma prepared in Preparation Example 2 were pretreated at 1, 10, 30, 100 ⁇ g/ml concentrations for 1 hour, and then 1 ⁇ g/ml LPS concentration was added for 24 hours. During the treatment. Thereafter, the supernatant was taken and the change in the nitric oxide content was evaluated by measuring the absorbance at 520 and 550 nm wavelength values through the Griess assay kit (G2930, Promega, USA). The results are shown in FIG. 6.
- the negative control group (LPS) treated with only LPS produced higher levels of nitric oxide (1123%) compared to the non-LPS treatment group (normal group; NC).
- the complex herbal extracts were treated at concentrations of 1, 10, 30, and 100 ⁇ g/ml, the increase in nitric oxide production decreased at all concentrations.
- the complex herbal extracts were treated at concentrations of 10, 30, and 100 ⁇ g/ml, the negative control group Compared to that, they decreased by 56.4%, 91.4%, and 99.5%. Therefore, it was confirmed that the extract of the complex herbal medicine has excellent ability to inhibit the inflammatory response induced by LPS.
- a 5-week-old male C57BL/6 mouse (Orient Bio Inc., Republic of Korea) weighing 20-22 g was used. Animals were maintained at a room temperature of 23 ⁇ 1° C. under the conditions of a 12 hour day and 12 hour night cycle according to the guidelines of NIH (NIH publication No. 85-23, revised 1985). Mice were randomly divided into 5 groups as follows to perform an in vivo experiment.
- Rotarod test was performed to confirm motor functionality.
- the Rotarod test is a test that measures the running time on a rotating cylinder, and ROTA-ROD TREADMILL DJ345 (Daejong Machine Industries, Korea) was used. Before proceeding with this experiment, the mice were trained three times to run for 5 minutes on a cylinder rotating at a speed of 5, 15 rpm two days and a day before to become accustomed to the device.
- BV2 cells in DMEM medium (Gibco TM , USA) containing fetal bovine serum (Fetal Bovine Serum, FBS, Gibco TM , USA) and antibiotics (1% Penicillin, Streptomycin [P/S] Gibco-BRL, USA) Cultured. Specifically, the incubator was kept at a temperature of 37°C, and a gas mixed with 95% air and 5% CO2 was continuously supplied to ensure that appropriate conditions for cell culture were established. Cells were cultured 24 hours before the experiment so that the cells were 3x10 4 cells/well in a 12-well plate.
- the complex herbal extracts of Wonhwa, Wiryeongseon and Chunma prepared in Preparation Example 2 and the complex herbal extracts of Wiryeongseon and Cheonma prepared in Preparation Example 3 were pretreated at a concentration of 10 ⁇ g/ml for one hour, and then 1 ⁇ g LPS at a concentration of /ml was treated for 24 hours. Thereafter, the supernatant was taken and the change in the nitric oxide content was evaluated by measuring the absorbance at 520 and 550 nm wavelength values through the Griess assay kit (G2930, Promega, USA). The results are shown in FIG. 8.
- the negative control group (LPS) treated with only LPS produced higher levels of nitric oxide (1123%) compared to the non-LPS treatment group (normal group; NC).
- the complex herbal extracts of Wonhwa, Wiryeongseon and Chunma (indicated as “complex herbal extracts” in Fig. 8) and the complex herbal extracts of Wiryeongseon and Chunma (indicated as “wiryeongseon/cheonma complex extracts” in Fig.
- general symptom changes such as weight change and vomiting in beagle dogs after oral administration of a compound herbal extract according to a combination ratio of 1:1:1, 1:5:5 or 1:10:10 of Wonhwa, Wiryeongseon and Chunma was observed.
- Beagle dogs used in the test were 5 males and females (male G1101, G1201, G1301, G1401, G1501; female G2101, G2201, and females) aged 9-14 months (Beijing Marshall Biotechnology Co., Ltd., China) G2301, G2401, G2501) was used, and the test substances were prepared in Preparation Example 4-1 (mixing ratio 1:1:1), 4-2 (1:5:5), and 4-3 (1:10:10).
- the freeze-dried powder prepared by was weighed according to the required amount and suspended in water for injection (JW Joongwae Pharmaceutical, Korea) and prepared on the day of administration, or it was used by filling it in general gelatin capsules or enteric capsules the day before administration.
- the amount of liquid to be administered was 5 ml/kg body weight.
- the test design was conducted as shown in Table 2, and the test was conducted with a wash-out period of at least 5 days or more for each test.
- Example 4-1 50 mg/kg single 2 G1101 G2101 Manufacturing Example 4-1 50 mg/kg single Filled in general gelatin capsules and administered 3 G1201 G2201 Manufacturing Example 4-1 50 mg/kg single Filled in enteric capsules and administered 4 G1101, G1201 G2101, G2201 Manufacturing Example 4-1 25 mg/kg once a day for 4 days 5 G1101 G2101 Manufacturing Example 4-2 41.25 mg/kg once a day for 5 days 6 G1301, G1401 G2301, G2401 Manufacturing Example 4-3 50 mg/kg single 7 G1501 G2501 Manufacturing Example 4-3 100 mg/kg once a day for 7 days
- human neuroblastoma SH-SY5Y cells contain 10% fetal bovine serum (Fetal Bovine Serum, FBS, Gibco TM , USA) and antibiotics (1% Penicillin, Streptomycin [P/S], Gibco-BRL, USA) DMEM medium (Gibco TM , USA) was cultured in the medium.
- the incubator was kept at a temperature of 37°C, and a gas mixed with 95% air and 5% CO2 was continuously supplied to obtain appropriate conditions for cell culture. Cells were cultured 24 hours before the experiment so that it became 4 ⁇ 10 5 cells/ml. When an appropriate number of cells were cultured, the cells were differentiated by replacing them with a medium containing 0.5% FBS and cultured for an additional 20 hours.
- the SH-SY5Y cell line is cultured in a 96-well plate prepared in Preparation Examples 4-1, 4-2, and 4-3 of Wonhwa, Wiryeongseon and Chunma 1:1:1, 1:5:5, 1:10
- the :10 complex herbal extracts were treated at concentrations of 3, 10, and 30 ⁇ g/ml, respectively, for 4 hours, followed by treatment with 1 mM MPP+. After 44 hours of MPP+ treatment, 100 ⁇ l of MTT solution at a concentration of 1 mg/ml was added to a 96-well plate. After reacting in an incubator at 37° C. for 1 hour and removing the MTT solution, 100 ⁇ l/well of 100% DMSO was added, shaking for about 15 minutes, and absorbance was measured at a wavelength of 570 nm.
- the cell survival rate was 55.6% in the negative control group treated with MPP+ compared to the non-MPP+ treatment group (normal group; NC), and statistically significant cell death was confirmed.
- the complex herbal extracts having a combination ratio of 1:1:1, 1:5:5, and 1:10:10 were treated at concentrations of 3, 10, and 30 ⁇ g/ml, respectively, 1:1:1 complex herbal extracts (10, 30 ⁇ g/ml), 1:5:5 complex herbal extract (3, 10, 30 ⁇ g/ml), 1:10:10 complex herbal extract (10, 30 ⁇ g/ml) by MPP+ It was suppressed in a concentration-dependent manner.
- the 1:10:10 complex herbal extract treatment group exhibited the highest cytoprotective activity at the same concentration compared to the 1:1:1 or 1:5:5 complex herbal extract treatment group, It was confirmed that it has excellent neuronal cell protection efficacy.
- 1:1:1, 1:5:5, and 1:10:10 complex herbal extracts of Wonhwa, Wiryeongseon and Chunma prepared in Preparation Examples 4-1, 4-2, and 4-3 were respectively used for the same cells.
- 50 ⁇ M of 6-OHDA was treated instead of MPP+ as a neurocytotoxic inducing substance.
- absorbance was measured in the same manner as MPP+, and the results are shown in FIG. 9B, and the cytoprotective effects on 6-OHDA neurotoxicity were 1:1:1, 1:5:5, It was similar in the complex herbal extracts according to the 1:10:10 combination ratio.
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) inhibits mitochondrial activity by inhibiting the mitochondrial electron transport system. In this case, brain cells are killed, resulting in decreased motor function. Therefore, in order to verify the effect of improving the behavioral ability of the extract of the complex herbal medicine, an experiment was performed to confirm the motor function in an MPTP-induced Parkinson's disease animal model.
- mice 8-week-old male C57BL/6J mice (DBL Inc., Korea) were used in the experiment after a 5-day acclimatization period. Animals were maintained at a room temperature of 23 ⁇ 1° C. with 12 hours of daytime and 12 hours of night cycle following the guidelines of NIH (NIH publication No. 85-23, revised 1985). Mice were randomly divided into 5 groups as follows to perform an in vivo experiment.
- the extracts were each orally administered to mice for 12 days.
- 30 mg/kg/day MPTP dissolved in saline was administered intraperitoneally for 5 days from the start of the extract administration (intraperitoneal injection, i.p.).
- Pole test was performed to confirm the functionality of the rotational motion. Pole test is a test that measures the time it takes for the mouse to rotate downward by placing the mouse upward at the upper end of the vertical bar. Training was conducted twice.
- the mouse was placed at the upper end of the vertical bar, and the time it took for the mouse to rotate the body in the downward direction was measured, and the results are shown in FIG. 10.
- the Rotarod test was performed to evaluate the overall athletic ability.
- the Rotarod test is a test that evaluates motor ability by placing an experimental animal on a rotating cylinder, and was conducted using ROTA-ROD TREADMILL (Jeongdo B&P, Korea). Before proceeding with this experiment, training was performed twice so that the mice run for 3 minutes on a cylinder rotating at a speed of 9 rpm one day before to become accustomed to the device. In this experiment, the number of times that the mouse ran for 3 minutes on a cylinder rotating at 11 rpm and then fell to the floor was measured, and the results are shown in FIG. 11.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
중량비 (w/w) | 원생약 총량(g) | 수율(%) | |||
원화 | 위령선 | 천마 | |||
제조예 4-1 | 1 | 1 | 1 | 1200 | 17.3 |
제조예 4-2 | 1 | 5 | 5 | 55 | 17.7 |
제조예 4-3 | 1 | 10 | 10 | 315 | 7.7 |
시험 번호 | 개체번호 | 투여물질 | 투여기간 및 용량 | 비고 | |
수컷 | 암컷 | ||||
1 | G1101 | G2101 | 제조예 4-1 | 50 mg/kg 단회 | |
2 | G1101 | G2101 | 제조예 4-1 | 50 mg/kg 단회 | 일반 젤라틴캡슐에 충진하여 투여 |
3 | G1201 | G2201 | 제조예 4-1 | 50 mg/kg 단회 | 장용캡슐에충진하여 투여 |
4 | G1101, G1201 | G2101, G2201 | 제조예 4-1 | 25 mg/kg1일 1회 4일간 | |
5 | G1101 | G2101 | 제조예 4-2 | 41.25 mg/kg1일 1회 5일간 | |
6 | G1301, G1401 | G2301, G2401 | 제조예 4-3 | 50 mg/kg 단회 | |
7 | G1501 | G2501 | 제조예 4-3 | 100 mg/kg1일 1회 7일간 |
몸무게 (kg) | 개체번호 | 시험번호 | ||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | ||
수컷 | G1101 | 7.19 | 7.51 | - | 7.94 | 8.75 | - | |
암컷 | G2101 | 6.49 | 6.51 | - | 6.93 | 7.2 | - | |
수컷 | G1201 | - | - | 8.46 | 8.98 | - | - | |
암컷 | G2201 | - | - | 5.88 | 6.12 | - | - | |
수컷 | G1301 | - | - | - | - | - | 9.79 | |
암컷 | G2301 | - | - | - | - | - | 7.23 | |
수컷 | G1401 | - | - | - | - | - | 7.73 | |
암컷 | G2401 | - | - | - | - | - | 6.68 | |
수컷 | G1501 | - | - | - | - | - | - | 8.96 |
암컷 | G2501 | - | - | - | - | - | - | 7.06 |
시험번호 | 투여 물질 | 투여기간 및 용량 | 일반증상 관찰 결과 |
1 | 제조예 4-1 | 50 mg/kg 단회 | 암컷: 투여 후 30분-1시간 구토 관찰수컷: 투여 후 1시간 구토 관찰 |
2 | 제조예 4-1 | 50 mg/kg 단회(일반 젤라틴 캡슐 충진) | 암컷: 투여 후 1시간 구토 관찰수컷: 투여 후 30분 구토 관찰 |
3 | 제조예 4-1 | 50 mg/kg 단회(장용캡슐 충진) | 암수 모두 투여 후 30분-4시간 구토 관찰 |
4 | 제조예 4-1 | 25 mg/kg1일 1회 4일간 | 암컷: 투여 2-3일간 구토 관찰수컷: 투여 2-4일간 구토 관찰 |
5 | 제조예 4-2 | 41.25 mg/kg1일 1회 5일간 | 암수 모두 투여 1일째 구토 관찰, 이후 구토 없음 |
6 | 제조예 4-3 | 50 mg/kg 단회 | 암수 모두 구토 없음 |
7 | 제조예 4-3 | 100 mg/kg1일 1회 7일간 | 암컷에서만 투여 1일째 구토 관찰, 이후 구토 없음 |
Claims (21)
- 원화, 위령선, 및 천마로 이루어진 군으로부터 선택되는 두 가지 이상의 생약 추출물을 포함하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 생약 추출물은 원화, 위령선, 및 천마로 이루어진 군으로부터 선택되는 생약으로부터 추출된 추출물 각각을 포함하거나, 원화, 위령선, 및 천마로 이루어진 군으로부터 선택되는 생약의 혼합물로부터 추출된 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 생약 추출물은 물, C1 내지 C6의 알코올, 아세트산, 및 이들의 혼합 용매로 이루어지는 군으로부터 선택되는 용매로 추출된 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 생약 추출물은 0.01% 내지 90% 에탄올 추출물인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 생약 추출물은 50% 내지 70% 에탄올 추출물인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 신경퇴행성 질환은 파킨슨병, 알츠하이머병, 피크병, 헌팅톤병, 루게릭병, 프리온 질환, 루이소체 치매, 다계통 위축증, 진행성 핵상 마비, 프리드라이히 운동실조증, 측두엽 간질, 및 뇌졸중으로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 신경퇴행성 질환은 파킨슨병인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 원화 및 위령선의 생약 추출물을 포함하고, 원화 및 위령선의 배합 중량비는 1 : 1 내지 20인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 원화 및 천마의 생약 추출물을 포함하고, 원화 및 천마의 배합 중량비는 1 : 1 내지 20인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 위령선 및 천마의 생약 추출물을 포함하고, 위령선 및 천마의 배합 중량비는 1 : 0.05 내지 20인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물이 원화, 위령선, 및 천마의 생약 추출물을 포함하고, 원화, 위령선, 및 천마의 배합 중량비는 1 : 1 내지 20 : 1 내지 20인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제11항에 있어서, 원화, 위령선, 및 천마의 배합 중량비는 1 : 5 내지 15 : 5 내지 15인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제11항에 있어서, 원화, 위령선, 및 천마의 배합 중량비는 1 : 10 : 10인 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 행동 능력을 향상시키는 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 신경세포에서 독성에 의한 세포 사멸을 억제하는 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 신경세포에서 활성산소종(ROS)의 생성을 억제하는 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 신경세포에서 미토콘드리아의 기능을 보호하는 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 신경세포의 아폽토시스를 억제하는 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 약학 조성물은 산화질소(NO)의 생성을 억제하는 것을 특징으로 하는, 신경퇴행성 질환의 예방 또는 치료용 약학 조성물.
- 원화, 위령선, 및 천마로 이루어진 군으로부터 선택되는 두 가지 이상의 생약 추출물을 포함하는, 신경퇴행성 질환의 예방 또는 개선용 식품 조성물.
- 원화, 위령선, 및 천마로 이루어진 군으로부터 선택되는 두 가지 이상의 생약 추출물을 포함하는, 신경퇴행성 질환의 예방 또는 개선용 사료 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20873461.6A EP4043024A4 (en) | 2019-10-10 | 2020-10-08 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES WITH A MIXED HERBAL EXTRACT OF GENKWAE FLOS, CLEMATIDIS RADIX AND GASTRODIAE RHIZOMA |
JP2022520861A JP7361903B2 (ja) | 2019-10-10 | 2020-10-08 | 芫花、威霊仙、及び天麻の複合生薬抽出物を含む神経変性疾患の予防または治療用組成物 |
CN202080070492.5A CN114929253A (zh) | 2019-10-10 | 2020-10-08 | 包含芫花、威灵仙及天麻的复合生药提取物的用于预防或治疗神经退行性疾病的组合物 |
CA3153252A CA3153252A1 (en) | 2019-10-10 | 2020-10-08 | Composition for preventing or treating neurodegenerative diseases containing mixed herbal extract of genkwae flos, clematidis radix, and gastrodiae rhizoma |
US17/767,604 US20230263852A1 (en) | 2019-10-10 | 2020-10-08 | Composition For Preventing Or Treating Neurodegenerative Diseases Containing Mixed Herbal Extract Of Genkwae Flos, Clematidis Radix, And Gastrodiae Rhizoma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190125714 | 2019-10-10 | ||
KR10-2019-0125714 | 2019-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021071321A1 true WO2021071321A1 (ko) | 2021-04-15 |
Family
ID=75437379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/013812 WO2021071321A1 (ko) | 2019-10-10 | 2020-10-08 | 원화, 위령선, 및 천마의 복합 생약 추출물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230263852A1 (ko) |
EP (1) | EP4043024A4 (ko) |
JP (1) | JP7361903B2 (ko) |
KR (1) | KR102310764B1 (ko) |
CN (1) | CN114929253A (ko) |
CA (1) | CA3153252A1 (ko) |
WO (1) | WO2021071321A1 (ko) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110138531A (ko) * | 2010-06-21 | 2011-12-28 | 건국대학교 산학협력단 | 신경 세포사 억제 활성을 갖는 천마 추출물을 포함하는 뇌질환의 예방 및 치료용 약학 조성물 |
KR101166481B1 (ko) | 2010-05-14 | 2012-07-19 | 경희대학교 산학협력단 | 목단피 추출물을 함유하는 파킨슨병 예방 및 치료용 조성물 |
CN103432426A (zh) * | 2013-09-13 | 2013-12-11 | 袁训辉 | 一种治疗神经性肌肉萎缩的中药片剂及其制备方法 |
KR101436017B1 (ko) | 2011-01-26 | 2014-08-29 | 경희대학교 산학협력단 | 백렴 추출물을 유효성분으로 함유하는 치매 또는 파킨슨병 예방 및 치료용 조성물 |
KR20160058992A (ko) * | 2014-11-11 | 2016-05-26 | 강원대학교산학협력단 | 위령선 추출물을 함유하는 치매 예방 또는 치료 또는 인지능 개선용 조성물 |
KR101859196B1 (ko) * | 2016-11-14 | 2018-05-17 | 한국생명공학연구원 | 팥꽃나무 꽃 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경퇴행성 질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103533948A (zh) * | 2011-03-29 | 2014-01-22 | 百疗医株式会社 | 神经疾病的治疗及记忆力减退改善用生药组合物 |
CN102335348A (zh) * | 2011-10-09 | 2012-02-01 | 北京科莱博医药开发有限责任公司 | 一种用于防治帕金森氏病的天麻植物提取物及其制备方法 |
CN104547897A (zh) * | 2014-12-09 | 2015-04-29 | 张祺 | 一种治疗帕金森病的中药组合物 |
-
2020
- 2020-10-08 CN CN202080070492.5A patent/CN114929253A/zh active Pending
- 2020-10-08 JP JP2022520861A patent/JP7361903B2/ja active Active
- 2020-10-08 EP EP20873461.6A patent/EP4043024A4/en active Pending
- 2020-10-08 KR KR1020200130585A patent/KR102310764B1/ko active IP Right Grant
- 2020-10-08 CA CA3153252A patent/CA3153252A1/en active Pending
- 2020-10-08 WO PCT/KR2020/013812 patent/WO2021071321A1/ko unknown
- 2020-10-08 US US17/767,604 patent/US20230263852A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101166481B1 (ko) | 2010-05-14 | 2012-07-19 | 경희대학교 산학협력단 | 목단피 추출물을 함유하는 파킨슨병 예방 및 치료용 조성물 |
KR20110138531A (ko) * | 2010-06-21 | 2011-12-28 | 건국대학교 산학협력단 | 신경 세포사 억제 활성을 갖는 천마 추출물을 포함하는 뇌질환의 예방 및 치료용 약학 조성물 |
KR101436017B1 (ko) | 2011-01-26 | 2014-08-29 | 경희대학교 산학협력단 | 백렴 추출물을 유효성분으로 함유하는 치매 또는 파킨슨병 예방 및 치료용 조성물 |
CN103432426A (zh) * | 2013-09-13 | 2013-12-11 | 袁训辉 | 一种治疗神经性肌肉萎缩的中药片剂及其制备方法 |
KR20160058992A (ko) * | 2014-11-11 | 2016-05-26 | 강원대학교산학협력단 | 위령선 추출물을 함유하는 치매 예방 또는 치료 또는 인지능 개선용 조성물 |
KR101859196B1 (ko) * | 2016-11-14 | 2018-05-17 | 한국생명공학연구원 | 팥꽃나무 꽃 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경퇴행성 질환 예방 또는 치료용 약학 조성물 |
Non-Patent Citations (2)
Title |
---|
BAEK-SOO HAN, KYOUNG-SHIM KIM, YU JIN KIM, HOE-YUNE JUNG, YOUNG-MI KANG, KYU-SUK LEE, MI-JIN SOHN, CHUN-HYUNG KIM, KWANG-SOO KIM, : "Daphnane Diterpenes from Daphne genkwa Activate Nurr1 and Have a Neuroprotective Effect in an Animal Model of Parkinson’s Disease", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 79, no. 6, 24 June 2016 (2016-06-24), US, pages 1604 - 1609, XP055486196, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.6b00110 * |
MCGEER PLMCGEER EG: "Glial reactions in Parkinson's disease", MOV DISORD, vol. 23, no. 4, 2008, pages 474 - 83 |
Also Published As
Publication number | Publication date |
---|---|
US20230263852A1 (en) | 2023-08-24 |
JP2022551290A (ja) | 2022-12-08 |
CN114929253A (zh) | 2022-08-19 |
CA3153252A1 (en) | 2021-04-15 |
KR20210042837A (ko) | 2021-04-20 |
JP7361903B2 (ja) | 2023-10-16 |
KR102310764B1 (ko) | 2021-10-08 |
EP4043024A1 (en) | 2022-08-17 |
EP4043024A4 (en) | 2023-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018012834A1 (ko) | 퇴행성 뇌질환 또는 대사성 질환의 예방 또는 치료 효과를 가지는 아커만시아 뮤시니필라 균주 및 이의 용도 | |
WO2016032249A1 (ko) | 모새나무 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020180025A1 (ko) | 스피룰리나 추출물 제조방법, 스피룰리나 추출물을 포함하는 인지능 개선용 약학적 조성물 및 건강기능식품 | |
WO2010058926A2 (ko) | 생강 추출물 또는 쇼가올을 포함하는 약학 조성물 | |
WO2021049864A1 (ko) | 두릅나무 추출물을 함유하는 안구건조증 개선용 조성물 | |
WO2012050397A2 (ko) | 생약 추출물을 포함하는 신장암 예방 또는 치료용 약학적 조성물 | |
WO2019177428A1 (ko) | 호흡기 질환의 예방 또는 치료용 생약 조성물 | |
WO2016006947A1 (ko) | 환삼덩굴 추출물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
WO2021091164A1 (ko) | 장미 추출물을 유효성분으로 함유하는 비만 또는 알레르기의 예방 또는 치료용 약학적 조성물 | |
WO2011139118A2 (en) | A pharmaceutical composition and a health functional food composition for preventing, treating or improving a gastrointestinal dyskinetic disease | |
WO2014109587A1 (ko) | 천연 추출물을 포함하는 당뇨합병증 또는 혈관부종의 예방 또는 치료용 약학적 조성물 및 건강기능식품 조성물 | |
WO2021071321A1 (ko) | 원화, 위령선, 및 천마의 복합 생약 추출물을 포함하는 신경퇴행성 질환의 예방 또는 치료용 조성물 | |
WO2020101442A1 (ko) | 견사단백질을 갖는 익힌 누에가공물 및 당귀 추출물을 함유하는 기억력 개선용 조성물 또는, 알츠하이머성 치매 예방 및 치료용 조성물 | |
WO2016032250A1 (ko) | 채송화 추출물 또는 이의 분획물을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌신경 질환의 예방 또는 치료용 약학적 조성물 | |
WO2016129902A1 (ko) | 번아웃증후군의 예방, 개선 또는 치료용 조성물 | |
WO2022211396A1 (ko) | 배암차즈기 추출물 또는 이의 유래 화합물을 유효성분으로 포함하는 근위축 예방 또는 치료용 약학적 조성물 | |
WO2019124854A1 (ko) | 혼합 추출물 또는 이의 분획물을 포함하는 안구건조증 예방 또는 치료용 조성물 | |
WO2022163971A1 (ko) | 콜린에스터라제 억제제 및 항산화제를 포함하는 뇌질환 치료용 약학적 복합 조성물 | |
WO2014157811A1 (ko) | 류마티스 관절염 및 골관절염의 개선 또는 치료를 위한 조성물 | |
WO2012105816A2 (ko) | 새콩 분말 또는 이의 추출물을 포함하는 당뇨병 및 당뇨합병증 예방 및 치료를 위한 조성물 | |
WO2010090423A2 (en) | Composition comprising combined crude drug extract for preventing and treating hyperlipidemia and diabetic hyperlipidemia | |
WO2019231198A1 (ko) | 승마 추출물, 이의 분획물 또는 승마에서 유래된 화합물을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 조성물 | |
WO2019098568A2 (ko) | 동백나무 추출물을 포함하는 통증의 완화, 예방 또는 치료용 조성물 | |
WO2023182757A1 (ko) | 뇌졸중의 예방 및 치료용 조성물 | |
WO2020071620A1 (ko) | 참당귀 추출물 또는 참당귀 및 브로콜리의 혼합 추출물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20873461 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3153252 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022520861 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020873461 Country of ref document: EP Effective date: 20220510 |